放射性配体疗法在晚期恶性肿瘤中的应用现状及进展  

Current Status and Progress of Radioligand Therapy in Advanced Malignant Tumors

作　　者：邱大胜[1] James Nagarajah 崔殿生[3] 魏少忠[3] QIU Dasheng;James NAGARAJAH;CUI Diansheng;WEI Shaozhong(Department of Radiology and Nuclear Medicine,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430079,China;Department of Radiology and Nuclear Medicine,Radboud University Medical Center,Nijmegen NB6511,Holland;Department of Urology,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430079,China)

机构地区：[1]湖北省肿瘤医院核医学科,武汉430079 [2]拉德堡德大学医学中心核医学科,奈梅亨NB6511 [3]湖北省肿瘤医院泌尿肿瘤外科,武汉430079

出　　处：《肿瘤防治研究》2025年第2期110-117,共8页Cancer Research on Prevention and Treatment

摘　　要：1946年,放射性碘131被报道首次用于治疗分化型甲状腺癌。然而,鉴于早期核药技术的限制以及缺乏特异性,核素治疗的疗效及不良反应限制了其在临床的广泛使用。近年来科学家和临床医生通过将放射性同位素与靶向部分(如肿瘤特异性小分子、肽或抗体)联系起来,努力开发更安全、更有效的核药。随着镭-223、Lutathera(镥-177)和Pluvicto(177Lu-PSMA-617)相继进入临床。放射性配体疗法逐渐在不同肿瘤中展现出较好疗效。本文聚焦治疗性放射性配体药物在晚期恶性肿瘤应用现状及最新的研究成果和治疗策略,助力实现更精准、个性化的治疗方式,从而提高疗效和减轻不良反应。In 1946,radioactive iodine 131 was first used for the treatment of differentiated thyroid cancer.However,the limitations of early nuclear medicine technology,the lack of specificity,the efficacy of nuclide therapy,and its adverse effects have limited its widespreadly clinical application.In recent years,scientists and clinicians have linked radioisotopes to targeted parts(tumor-specific small molecules,peptides,or antibodies)to develop safe and effective nuclear drugs.Ra-223,Lutathera(lutetium-177),and Pluvicto(177Lu-PSMA-617)have been successfully used in clinical treatment.Radioligand therapy has gradually shown good efficacy in different tumors.This paper focuses on the current situation of the application of therapeutic radioligand drugs in advanced malignant tumors and the latest research results and treatment strategies to achieve more accurate and personalized treatment methods,thereby to improve the curative effect,and reduce adverse reactions.

关 键 词：放射性配体疗法 恶性肿瘤 晚期 

分 类 号：R730.55[医药卫生—肿瘤]